GlassScriptPhysician profile
Bryce Abbe Manton
NPI 1326721523
$2,204.12
in general payments reported to CMS, 2019-2025
15 companies · $927 in 2025
The $927 reported for 2025 was more than what 94% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,277 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.17 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.20 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $286.66 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $261.91 | 2024-2025 | |
| Lilly USA, LLC | $254.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $138.50 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $75.46 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.82 | 2025 | Jardiance |
| Globus Medical, INC. | $44.23 | 2025 | Senza |
| Tris Pharma INC | $37.21 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $33.03 | 2024-2025 | Trintellix |
| Mayne Pharma Commercial LLC | $29.36 | 2025 | |
| Abbott Laboratories | $24.60 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $17.78 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $17.51 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Manton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.